DAFTAR PUSTAKA

1. Sadock BJ, Sadock VA, Ruiz P. Kaplan & Sadock’s Synopsis of Psychiatry :

Behavioral Sciences/Clinical Psychiatry. 11th ed. Philadelphia: Lippincott

Wolters Kluwer ; 2015, p. 347-86.

2. Marvel CL, Paradiso S. Cognitive and Neurological Impairment in Mood

Disorders. Psychiatric Clinics. 2004;27(1):19-36.

3. Syafwan AF, Sedjahtera K, Asterina A. Gambaran Peningkatan Angka

Kejadian Gangguan Afektif dengan Gejala Psikotik pada Pasien Rawat Inap

di RSJ Prof. Dr. HB. Sa’anin Padang pada Tahun 2010-2011. Jurnal

Kesehatan Andalas. 2014;3(2).

4. Amare AT, Schubert KO, Baune BT. Pharmacogenomics in The Treatment

of Mood Disorders: Strategies and Opportunities for Personalized Psychiatry.

EPMA Journal. 2017;8(3):211-27.

5. Malhi GS, Bassett D, Boyce P, Bryant R, Fitzgerald PB, Fritz K, Hopwood

M, Lyndon B, Mulder R, Murray G, Porter R. Royal Australian and New

Zealand College of Psychiatrists Clinical Practice Guidelines for Mood

Disorders. Australian & New Zealand Journal of Psychiatry. 2015

Dec;49(12):1087-206.

6. Maslim R. Panduan Praktis Penggunaan Klinis Obat Psikotropik

(Psychotropic Medication), Edisi 2014. Bagian Ilmu Kedokteran Jiwa FK-

Unika Atmajaya, Kompleks RS Atmajaya:2014.p.34-39.

66
7. Vieta E, Sanchez-Moreno J. Acute and Long-term Treatment of Mania.

Dialogues in Clinical Neuroscience. 2008(2):165.

8. Katzung, B.G., Masters, S.B. dan Trevor, A.J. Farmakologi Dasar & Klinik,

Vol.2, Edisi 12, Editor Bahasa Indonesia Ricky Soeharsono et al., Penerbit

Buku Kedokteran EGC, Jakarta. 2014. P 501-41.

9. Macritchie K, Geddes J, Scott J, Haslam DR, de Lima MS, Goodwin G.

Valproate For Acute Mood Episodes in Bipolar Disorder. Cochrane Database

of Systematic Reviews. 2003(1).

10. Zannah U, Puspitasari IM, Sinuraya RK. Farmakoterapi Gangguan Bipolar.

Farmaka. 2018;16(1):263-77.

11. Schloesser RJ, Martinowich K, Manji HK. Mood-stabilizing drugs:

mechanisms of action. Trends in neurosciences. 2012;35(1):36-46.

12. Alsarra IA, Al‐Omar M, Belal F. Valproic acid and sodium valproate:

comprehensive profile. Profiles of Drug Substances, Excipients and Related

Methodology. 2005;32:209-40.

13. Gonda X, Pompili M, Serafini G, Montebovi F, Campi S, Dome P, Duleba T,

Girardi P, Rihmer Z. Suicidal behavior in bipolar disorder: epidemiology,

characteristics and major risk factors. Journal of affective disorders.

2012;143(1-3):16-26.

14. ESEMeD/MHEDEA 2000 investigators, Alonso J, Angermeyer MC, Bernert

S, Bruffaerts R, Brugha TS, Bryson H, de Girolamo G, de Graaf R,

Demyttenaere K, Gasquet I. Psychotropic drug utilization in Europe: results

67
 from the European Study of the Epidemiology of Mental Disorders

(ESEMeD) project. Acta Psychiatrica Scandinavica. 2004;109:55-64.

15. Zito JM, Safer DJ, Janhsen K, Fegert JM, Gardner JF, Glaeske G, Valluri SC.

A three-country comparison of psychotropic medication prevalence in youth.

Child and adolescent psychiatry and mental health. 2008;2(1):26.

16. Post RM, Denicoff KD, Frye MA, Dunn RT, Leverich GS, Osuch E, Speer

A. A history of the use of anticonvulsants as mood stabilizers in the last two

decades of the 20th century. Neuropsychobiology. 1998;38(3):152-66.

17. Kessing LV, Bauer M, Nolen WA, Severus E, Goodwin GM, Geddes J.

Effectiveness of maintenance therapy of lithium vs other mood stabilizers in

monotherapy and in combinations: a systematic review of evidence from

observational studies. Bipolar disorders. 2018;20(5):419-31.

18. Shorter E. The history of lithium therapy. Bipolar disorders. 2009;11:4-9.

19. Bushnell GA, Compton SN, Dusetzina SB, Gaynes BN, Brookhart MA,

Walkup JT, Rynn MA, Stürmer T. Treating pediatric anxiety: Initial use of

SSRIs and other anti-anxiety prescription medications. The Journal of clinical

psychiatry. 2018;79(1).

20. Alda M. Lithium in the treatment of bipolar disorder: pharmacology and

pharmacogenetics. Molecular psychiatry. 2015;20(6):661-70.

21. Ayano G. Bipolar disorders and carbamazepine: Pharmacokinetics,

pharmacodynamics, therapeutic effects and indications of carbamazepine:

review of articles. J Neuropsychopharmacol Ment Health. 2016;1(112):2.

68
22. Ayano G. Bipolar disorders and valproate: Pharmacokinetics,

pharmacodynamics and therapeutic effects and indications of valproate:

review of articles. Bipolar Disord. 2016;2(109):2472-1077.

23. Wyszynski DF, Nambisan M, Surve T, Alsdorf RM, Smith CR, Holmes LB.

Increased rate of major malformations in offspring exposed to valproate

during pregnancy. Neurology. 2005;64(6):961-5.

24. Chaudrey KH, Naser TB, Steinberg A, Avashia KD, Nouri-kolouri M, Asadi

S, Khan SI, Ihsan M. Thinking beyond the obvious: hepatotoxicity secondary

to idiosyncratic depakote toxicity. American journal of therapeutics.

2012;19(6):403-6.

25. Pellock JM, Wilder BJ, Deaton R, Sommerville KW. Acute pancreatitis

coincident with valproate use: a critical review. Epilepsia. 2002;43(11):1421-

4.

26. Nguyen H, Kitzmiller JP, Osuagwu F, Chandran V, Khungar P. Valproate

acid (Depakote) induced hyperammonemic encephalopathy in the pediatric

populations. J Pediatr Neurol Disord. 2017;3(116):2.

27. NDA. Depakote (divalproex sodium) Tablets for Oral use FDA Approved

Labeling Text dated October 7, 2011.

69